CD19 and graft versus host disease: Furthermore, encouraging complete response rates without any GvHD or neurotoxicity (and only grade 1–2 CRS) were recently reported in relapsed B-ALL patients after allo-HSCT using donor-derived anti-CD19-CAR-CIK cells (NCT03389035) (18).